Expression of VEGF and PEDF in Choroidal Neovascular Membranes Following Verteporfin Photodynamic Therapy

American Journal of Ophthalmology

Volumn 142, Issue 1, 2006, Pages

  Tatar, Olcay ^a   Adam, Annemarie ^b   Shinoda, Kei ^c   Stalmans, Peter ^d   Eckardt, Claus ^e   Lüke, Matthias ^a   Bartz Schmidt, Karl Ulrich ^a   Grisanti, Salvatore ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c National Institute of Sensory Organs   (Japan)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Eye Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CD34 ANTIGEN; CYTOKERATIN 18; ENDOGLIN; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN; VISUAL PIGMENT;

ADULT; AGED; ARTICLE; CHRONOLOGY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VASCULARIZATION;

EID: 33745443689     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2006.01.085     Document Type: Article

References (55)

1. Hyman L. Epidemiology of eye disease in the elderly. Eye 1 (1987) 330-341
2. Bressler N., Bressler S., and Fine S. Age related macular degeneration. Surv Ophthalmol 32 (1988) 375-413
3. Guyer D., Fine S., Maguire M., et al. Subfoveal choroidal neovascular membranes in age related macular degeneration. visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol 104 (1986) 702-705
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. one-year results of 2 randomized clinical trials-TAP report No. 1. Arch Ophthalmol 117 (1999) 1329-1345
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. two-year results of 2 randomized clinical trials-TAP report No. 2. Arch Ophthalmol 119 (2001) 198-207
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration. additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 120 (2002) 1443-1454
7. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration. two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report No. 2. Am J Ophthalmol 131 (2001) 541-560
8. Blinder K.J., Bradley S., Bressler N.M., et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (2003) 407-418
9. Schmidt-Erfurth U., and Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45 (2000) 195-214
10. Bressler N.M., Bressler S.B., Childs A.L., et al., Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report No. 13. Ophthalmology 111 (2004) 1993-2006
11. Mruthyunjaya P., Stinnett S.S., and Toth C.A. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology 111 (2004) 1715-1724
12. van Meurs J.C., and van Den Biesen P.R. Autologous retinal pigment epithelium and choroid translocation in patients with exudative age-related macular degeneration. short-term follow-up. Am J Ophthalmol 136 (2003) 688-695
13. Park C.H., and Toth C.A. Macular translocation surgery with 360-degree peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 136 (2003) 830-835
14. Mirshahi A., Schreyger F., Baatz H., et al. Macular translocation after photodynamic therapy. a case report. Klin Monatsbl Augenheilkd 222 (2005) 586-589
15. Spaide R.F., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
16. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. phase II study results. Ophthalmology 110 (2003) 979-986
17. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
18. Grisanti S., Tatar O., Canbek S., et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am J Ophthalmol 137 (2004) 914-923
19. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
20. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 333 (1995) 1757-1763
21. Pepper M. Manipulating angiogenesis. from basic science to the bedside. Arterioscler Thromb Vasc Biol 17 (1997) 605-619
22. Kwak N., Okamoto N., Wood J., et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41 (2000) 3158-3164
23. Kvanta A., Algvere P.V., Berglin L., et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37 (1996) 1929-1934
24. Amin R., Pulkin J.E., and Frank R.N. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 35 (1994) 3178-3188
25. Lopez P.F., Sippy B.D., Lambert H.M., et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37 (1996) 855-868
26. Tatar O., Kaiserling E., Adam A., et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol (2006) Forthcoming
27. Bhutto I.A., McLeod D.S., Hasegawa T., et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 82 (2006) 99-110
28. Tombran-Tink J., Shivaram S.M., Chader G.J., et al. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 15 (1995) 4992-5003
29. Holekamp N.M., Bouck N., and Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 134 (2002) 220-227
30. Renno R.Z., Youssri A.I., Michaud N., et al. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43 (2002) 1574-1580
31. Mori K., Duh E., Gehlbach P., et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188 (2001) 253-263
32. Mori K., Gehlbach P., Yamamoto S., et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43 (2002) 1994-2000
33. Saishin Y., Silva R.L., and Saishin Y. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum Gene Ther 16 (2005) 473-478
34. Ogata N., Wada M., Otsuji T., et al. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43 (2002) 1168-1175
35. Matsuoka M., Ogata N., Otsuji T., et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 88 (2004) 809-815
36. Martin G., Schlunck G., Hansen L.L., et al. Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol 242 (2004) 321-326
37. Schmidt-Erfurth U., Michels S., Barbazetto I., et al. Photodynamic effects on choroidal neovascularization and physiological choroids. Invest Ophthalmol Vis Sci 43 (2002) 830-841
38. Schmidt-Erfurth U., Laqua H., Schlötzer-Schrehardt U., et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120 (2002) 835-844
39. Schlötzer-Schrehardt U., Vistenz A., Naumann G.O.H., et al. Dose-dependent structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240 (2002) 748-757
40. Schmidt-Erfurth U., and Michels S. Changes in confocal indocyanine green angiography through two years following photodynamic therapy with verteporfin. Ophthalmology 110 (2003) 1306-1314
41. Michels S., and Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44 (2003) 2147-2154
42. Shima D.T., Adamis A.P., Ferrara N., et al. Hypoxic induction of endothelial cell growth factors in retinal cells. identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1 (1995) 182-193
43. Smith L.E., Wesolowski E., McLellan A., et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35 (1994) 101-111
44. Schlingemann R.O. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242 (2004) 91-101
45. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor. a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
46. Notari L., Miller A., Martinez A., et al. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9. implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci 46 (2005) 2736-2747
47. Kuroki M., Voest E.E., Amano S., et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98 (1996) 1667-1675
48. Ohno-Matsui K., Morita I., Tombran-Tink J., et al. Novel mechanism for age-related macular degeneration. an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189 (2001) 323-333
49. Ohno-Matsui K., Yoshida T., Uetama T., Mochizuki M., and Morita I. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 11 (2003) 303 962-967
50. Schmidt-Erfurth U., Schlötzer-Schrehard U., Cursiefen C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44 (2003) 4473-4480
51. Spilsbury K., Garrett K.L., Shen W.Y., et al. Over-expression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157 (2000) 135-144
52. Campochiaro P.A., Nguyen Q.D., Shah S.M., et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration. results of a phase I clinical trial. Hum Gene Ther 17 (2006) 167-176
53. Bouck N. PEDF. anti-angiogenic guardian of ocular function. Trends Mol Med 8 (2002) 330-334
54. Tombran-Tink J., and Barnstable C.J. Therapeutic prospects for PEDF. more than a promising angiogenesis inhibitor. Trends Mol Med 9 (2003) 244-250
55. Apte R.S., Barreiro R.A., Duh E., Volpert O., and Ferguson T.A. Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest Ophthalmol Vis Sci 45 (2004) 4491-4497